<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView%20%20&amp;noscript=1">

White Papers


Precision Profiling

Oncology drug development has an overly high attrition rate for novel agents in late-phase clinical trials, which needs to be improved to enhance the efficiency and cost-effectiveness of developing new therapies. Precision profiling using Patient-Derived Xenografts (PDX), the most predictive preclinical models available, allows the identification of molecular biomarkers and genetic signatures of response for patient stratification to improve response and reduce attrition rates. Let CrownBio’s Precision Profiling White Paper help you understand who will benefit from your treatment before you enter the clinic.